TIRZ

Tirzepatide

Primary Function: Dual incretin agonist for weight loss and glycemic control
Research Use: Obesity, insulin resistance, type 2 diabetes, metabolic health
Molecular Formula: C225H348N48O68
CAS Number: 2023788-19-2
Synonyms: Mounjaro, LY3298176

Description:
Tirzepatide is a first-in-class dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This unique mechanism enhances insulin secretion, reduces appetite, and supports body weight reduction far beyond traditional GLP-1 agonists. Tirzepatide is widely studied for its effects on glycemic control, lipid metabolism, and obesity reversal, making it one of the most promising metabolic peptides in clinical research today.

Mechanism of Action:

• Binds to GIP and GLP-1 receptors
• Enhances glucose-dependent insulin secretion
• Suppresses glucagon and slows gastric emptying
• Amplifies satiety signaling in the brain

Key Research Areas:

• Obesity and long-term weight management
• Type 2 diabetes and insulin sensitivity
• Liver fat reduction and lipid control
• Appetite regulation and energy balance

History of Discovery:
Tirzepatide was developed by Eli Lilly and represents a novel class of dual-incretin agonists. It was approved by the FDA in 2022 under the brand name Mounjaro for the treatment of type 2 diabetes. Its development builds on decades of incretin hormone research, combining two pathways (GIP and GLP-1) for superior metabolic benefits over GLP-1 monotherapy alone.

Case Studies:

1. Superior Weight Loss in Obesity (2022, SURMOUNT-1 – NEJM): Participants lost up to 22.5% of body weight over 72 weeks with weekly Tirzepatide dosing. [N Engl J Med. 2022;387(3):205–216.]
2. Improved HbA1c and Lipid Markers (2021, SURPASS-2 Trial): Tirzepatide outperformed Semaglutide in reducing HbA1c, fasting glucose, and triglycerides in T2DM patients. [Lancet. 2021;398(10295):143–155.]
3. Liver Fat Reduction in NAFLD (2023, J Hepatol): MRI-based study confirmed significant reductions in liver fat content and fibrosis risk. [J Hepatol. 2023;78(1):123–132.]

Packaging Information:

• Form: Lyophilized powder or solution
• Purity: ≥ 99%
• For research use only. Not for human or veterinary use.